ProPhase Labs Seeks To Transform Esophageal Cancer Detection And Management With Launch Of Its BE-Smart Test In H2 2024
Portfolio Pulse from Benzinga Newsdesk
ProPhase Labs, Inc. (NASDAQ:PRPH) is set to launch its BE-Smart test for esophageal cancer detection in H2 2024. The test aims to provide early and cost-effective detection of esophageal adenocarcinoma (EAC), targeting a market size of $7 billion to $14 billion. The company is collaborating with mProbe Inc. and institutions like the Mayo Clinic for validation studies. The BE-Smart test, developed over six years, uses sophisticated proteomics for early detection and risk stratification of EAC, a cancer with high mortality rates. ProPhase plans to submit documentation for Advanced Diagnostic Laboratory Test (ADLT) application and aims for commercial launch following CPT code approval.
April 10, 2024 | 12:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ProPhase Labs is launching its BE-Smart test for esophageal cancer detection in H2 2024, aiming to capture a significant market share in the EAC diagnostics market. The test's development and anticipated launch could significantly impact the company's market position and financial performance.
The launch of the BE-Smart test represents a significant advancement in the field of esophageal cancer detection, potentially opening up a large market opportunity for ProPhase Labs. Given the test's innovative approach to early detection and risk stratification, along with the high mortality rate of EAC, there is a strong potential for positive market reception. This could lead to increased revenue streams and enhanced market positioning for ProPhase, positively impacting its stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100